According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “
Several other research analysts have also recently commented on IFRX. JPMorgan Chase & Co. cut Inflarx from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $67.00 to $9.00 in a research note on Wednesday, June 5th. Raymond James reissued a “hold” rating on shares of Inflarx in a report on Friday, July 19th. Guggenheim lowered Inflarx from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $65.00 to $6.00 in a report on Wednesday, June 5th. Robert W. Baird lowered Inflarx from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $58.00 to $6.00 in a report on Wednesday, June 5th. Finally, Leerink Swann lowered Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $15.66.
Inflarx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, May 23rd. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.19. Equities research analysts forecast that Inflarx will post -2.09 EPS for the current year.
A number of institutional investors have recently made changes to their positions in IFRX. FNY Investment Advisers LLC bought a new stake in Inflarx in the second quarter valued at about $884,000. Morgan Stanley increased its holdings in Inflarx by 454.5% in the second quarter. Morgan Stanley now owns 337,247 shares of the company’s stock valued at $1,066,000 after buying an additional 276,424 shares during the last quarter. FMR LLC bought a new stake in Inflarx in the first quarter valued at about $9,609,000. Redmile Group LLC increased its holdings in Inflarx by 7.2% in the first quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock valued at $82,482,000 after buying an additional 147,238 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Inflarx during the second quarter valued at approximately $445,000. 57.02% of the stock is owned by hedge funds and other institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Article: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.